Embolic Decision Making in Musculoskeletal Embolization

Elsevier

Available online 22 December 2022, 100879

Techniques in Vascular and Interventional RadiologyAuthor links open overlay panelAbstract

In his pioneering work, Okuno and colleagues demonstrated the benefit of musculoskeletal (MSK) embolization, using imipenem as an embolic agent, in various diseases such as knee osteoarthritis (KOA), adhesive capsulitis (AC), tennis elbow and other sports injuries. As imipenem is a last-resort, broad spectrum antibiotic, its use is often not feasible depending on countries and their drug regulation. Since then, several other studies have used other material products such as microparticles or liquid embolics. In addition, several products in development or that are used in other indications may prove useful after full clinical evaluation of safety and efficacy.

In this article we will develop our recommendations, through an analysis of recent publications on MSK embolization.

View full text

© 2022 Elsevier Inc. All rights reserved.

留言 (0)

沒有登入
gif